Health & Environmental Research Online (HERO)


Print Feedback Export to File
1836388 
Journal Article 
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer 
Ahn, J; Wee, WR; Lee, JH; Hyon, JY 
2011 
1 
Korean Journal of Ophthalmology
ISSN: 1011-8942
EISSN: 2092-9382 
25 
5 
355-357 
English 
21976946 
We report a case of vortex keratopathy in a patient treated with vandetanib for non-small cell lung cancer (NSCLC). A 44-year-old female who underwent two cycles of chemotherapy for NSCLC complained of visual blurring in both eyes after the initiation of vandetanib, an anti-epidermal growth factor receptor (EGFR) and anti-vascular endothelial growth factor receptor 2 protein tyrosine kinase inhibitor. On ophthalmic examination, visual acuities were 20 / 20 OU and, with the exception of diffuse vortex keratopathy in both eyes, other findings were unremarkable. Vandetanib is believed to have caused vortex keratopathy in this patient. Anti-EGFR properties affecting normal corneal epithelial cell migration and wound healing or drug associated metabolite deposition, which is the case in numerous drug-associated vortex keratopathies, may be possible underlying mechanisms in the formation of this corneal complication.